Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Effect of VIA-2291 on Vascular Inflammation

ClinicalTrials.gov ID: NCT00358826

Public ClinicalTrials.gov record NCT00358826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event

Study identification

NCT ID
NCT00358826
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Enrollment
191 participants

Conditions and interventions

Interventions

  • VIA-2291 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
30 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2006
Primary completion
Jul 31, 2008
Completion
Aug 31, 2008
Last update posted
Jul 22, 2012

2006 – 2008

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
MIMA Century Research Associates Melbourne Florida 32901
Minneapolis Heart Institute Minneapolis Minnesota 55407
Cardiology Associates Research, LLC Tupelo Mississippi 38801
LeBauer Cardiovascular Research Foundation Greensboro North Carolina 27401
Victoria Heart and Vascular Center Victoria Texas 77901

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00358826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2012 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00358826 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →